Literature DB >> 7754655

[Percutaneous lumbar nucleotomy with low-dose chymopapain, an ambulatory procedure].

T Hoogland1, C Scheckenbach.   

Abstract

100 patients, who underwent an automated percutaneous lumbar discectomy with low-dose chemonucleolysis, were controlled in this follow-up study after a minimum period of 2 years. They showed excellent or good results in 90% and fair in 8% of the cases. 2% of the patients showed unchanged symptoms. In 9% of the cases a microdiscectomy was necessary to reach this result. No severe intra- or postoperative complications like a postnucleotomy-syndrome were seen. A significant improvement was reached in radicular symptoms and back pain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7754655     DOI: 10.1055/s-2008-1039420

Source DB:  PubMed          Journal:  Z Orthop Ihre Grenzgeb        ISSN: 0044-3220


  4 in total

1.  Treatment of lumbar disc herniations by interventional fluoroscopy-guided endoscopy.

Authors:  Juergen Reul
Journal:  Interv Neuroradiol       Date:  2014-10-17       Impact factor: 1.610

2.  Endoscopic Transforaminal Lumbar Interbody Fusion With a Single Oblique PEEK Cage and Posterior Supplemental Fixation.

Authors:  Álvaro Dowling; Kai-Uwe Lewandrowski
Journal:  Int J Spine Surg       Date:  2020-10-29

3.  Artificial Intelligence Comparison of the Radiologist Report With Endoscopic Predictors of Successful Transforaminal Decompression for Painful Conditions of the Lumber Spine: Application of Deep Learning Algorithm Interpretation of Routine Lumbar Magnetic Resonance Imaging Scan.

Authors:  Kai-Uwe Lewandrowski; Narendran Muraleedharan; Steven Allen Eddy; Vikram Sobti; Brian D Reece; Jorge Felipe Ramírez León; Sandeep Shah
Journal:  Int J Spine Surg       Date:  2020-11-18

4.  Percutaneous transforaminal endoscopic surgery (PTES) for symptomatic lumbar disc herniation: a surgical technique, outcome, and complications in 209 consecutive cases.

Authors:  Yu-Tong Gu; Zhan Cui; Hong-Wei Shao; Yun Ye; Ai-Qun Gu
Journal:  J Orthop Surg Res       Date:  2017-02-08       Impact factor: 2.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.